December 6, 2022



Spexis Supplies Industry Replace and Pronounces Monetary Effects for the Complete-Yr 2021

  • A hit release of Spexis AG as a opposite merger of Polyphor AG with EnBiotix Inc.
  • A hit last of a USD 12.8 million pre-merger financing
  • First affected person enrollment and get started of Segment 1 trial for inhaled murepavadin
  • Get started of COPILOT, the primary a part of the Segment 3 ColiFin(R) program, in Q2 2022
  • Research of balixafortide building choices continues
  • Excellent growth in previous systems
  • Money available of CHF 14.4 million as of December 31, 2021 is anticipated to finance operations into Q3 2022

ALLSCHWIL, SWITZERLAND / ACCESSWIRE / March 24, 2022 / Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical corporate, fascinated about uncommon sicknesses and oncology with an preliminary center of attention on continual breathing sicknesses, as of late introduced its monetary effects for the full-year of 2021 and supplied a strategic industry replace.

On December 29, 2021, the corporate introduced the last of the pre-merger financing that preceded the announcement of the merger of EnBiotix, Inc. with Polyphor AG itself and the release of Spexis AG, which started buying and selling at the Swiss inventory change beneath the emblem “SPEX” (SIX:SPEX) on January 3, 2022.

“I’m very happy that we’re making excellent growth with Spexis as a singular uncommon illness and oncology corporate with an preliminary center of attention on continual breathing sicknesses, a box the place new remedy choices are urgently wanted. With a powerful proprietary place on our merchandise and analysis platforms, we’re taking part with main company companions, educational establishments and investigators all over the world – specifically within the box of Cystic Fibrosis,” says Jeff Bet, M.D., Chairman & CEO of Spexis. “Two medical systems are already underway, and our plan is to advance our portfolio of clinical-stage product applicants each by means of inside sources in addition to with further exterior partnerships. As well as, we will be able to proceed to construct and advance our leading edge R&D pipeline via additional medical trials, in-house pre-clinical systems and extra company acquisitions.”

Pipeline building

Spexis is to start with that specialize in uncommon, continual breathing sicknesses and plans to change into the most important participant in cystic fibrosis (“CF”). Even if CFTR modulators offered over the previous few years have led to vital development within the lung well being of CF sufferers, the choice of CF sufferers with moderate-to-severe lung disorder is projected to if truth be told build up over the following 20-30 years in consequence. And those sufferers are exactly those that would get advantages maximum from the corporate’s two medical program applicants ColiFin(R) and inhaled murepavadin.

See also  Amazon trots out YouTube-sized promoting industry

ColiFin(R), which EnBiotix in-licensed from PARI Pharma GmbH (a world chief in nebulized remedies) for international rights ex-Europe, is an inhaled cyclic polypeptide with specifically efficient job towards gram-negative pathogens and which acts by means of a distinct mechanism of motion in comparison to different licensed inhaled antibiotics. Licensed in Europe since 2010 as a front-line remedy for continual lung infections in CF, ColiFin(R) has a confirmed protection, efficacy, and industrial observe report which Spexis objectives to leverage in opposition to the U.S. and international markets – and each inside of and doubtlessly outdoor the sector of CF. The corporate has gained a “Learn about Might Continue” letter from the FDA to start up a unmarried Segment 3 trial of ColiFin(R) in grownup and adolescent topics with CF and persistent Pseudomonas aeruginosa (“PA”) lung infections that may strengthen a long run US New Drug Software (“NDA”) submission. The corporate is lately finalizing plans for beginning this Segment 3 program, with get started of COPILOT in the second one quarter 2022, enrollment of the primary affected person anticipated within the fourth quarter of 2022 and trial crowning glory projected for the 3rd quarter 2024.

Inhaled murepavadin (“iMPV”), a unique inhaled healing in particular concentrated on Pseudomonas aeruginosa (“PA”) was once found out from the corporate’s macrocyclic peptide era platform. Against this to maximum different antibiotics, murepavadin is pathogen-specific. This makes it a precision medication by means of design, and may be extremely potent towards PA. The Segment 1 iMPV find out about is comparing protection and tolerability of unmarried and more than one ascending doses of iMPV in wholesome volunteers. This find out about already began enrolling topics within the fourth quarter of 2021, with effects anticipated in the second one part of 2022, which might result in a Segment 1b/2 trial in 2023. As well as, there may be vital possible to increase iMPV for average to extreme non-CF bronchiectasis (“nCFBE”), which may be characterised by means of continual PA infections and is a marketplace a long way greater than the CF marketplace.

Balixafortide is a potent, particular and extremely selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor that regulates the trafficking and homing of each most cancers and immune gadget cells. CXCR4 is a promising goal for remedy of each hematologic and cast tumors, in addition to for different non-oncology indications. Following the termination of the Segment 3 FORTRESS find out about in complicated breast most cancers in 2021, Spexis has begun to guage further oncology and non-oncology indications for balixafortide and is doing so each on my own and in collaboration with Fosun Pharma, who has certified sure balixafortide rights from Spexis for the Chinese language marketplace. As well as, by means of the corporate’s proprietary discovery platform, Spexis is finding and creating a CXCR4/CXCR7 inhibitor pipeline fascinated about resistant hematologic malignancies, and for uncommon illness, anti inflammatory & anti-viral indications as smartly.

See also  10 Small Industry Advertising and marketing Methods That In reality Paintings

Monetary Effects

Within the complete 12 months of 2021, our general loss was once CHF 11.9 million, essentially pushed by means of monetary bills on account of the honest price adjustments of derivatives induced by means of the opposite merger and different working bills. R&D expenditures are anticipated to extend in 2022 as we get ready and release our Segment 3 trial for ColiFin(R). Spexis has finished a pre-merger financing of USD 12.8 million. This brings our general money place to CHF 14.4 million (money and money equivalents) as of December 31, 2021, which we predict to finance our operations into Q3 2022.

On October 28, 2021, Polyphor’s shareholders licensed all proposals of the Board of Administrators at Strange Normal Assembly with an important majority. This comprises approval of the rise of approved percentage capital, the rise of conditional percentage capital for bonds and an identical debt tools and the advent for of conditional percentage capital for worker get advantages plans. The entire licensed proposals have been topic to crowning glory of the merger which was once introduced on December 30, 2021.

Complete-year 2021 effects convention name and industry replace at 14.30 CET on March 24, 2022

Jeff Bet, M.D. (Chairman & CEO), Stephan Wehselau (COO), Juergen Froehlich, M.D. (CMDO) and Hernan Levett (CFO) will supply a industry and monetary replace, adopted by means of a Q&A consultation.

To get entry to the profits name, please use the next main points:

France: +33 (0)1 70 730 3 39

Germany: +49 (0)69 22222 5197

Italy: +39 02 3602 6066

Switzerland +41 (0)44 580 7279

United Kingdom +44 (0)330 165 4012

United States +1 646-828-8073

Match Name: Spexis AG – Technique Replace and 2021 Monetary Effects

See also  How To Get Began With Centered Electronic mail Advertising and marketing For Your Small Industry

Affirmation code: 4015509

The presentation may also be to be had by means of webcast:

Hyperlink for contributors of the convention name (simplest slides, no audio, no prolong):

After the decision, the presentation will likely be to be had by means of the above hyperlink.

Key figures 1

CHF million

Source of revenue Observation



General income



Analysis and building bills



Different working bills



Internet loss for the length



Stability Sheet



Money available



General belongings



General fairness



Moderate web money burn2



Collection of FTE



Fairness ratio in %



1) in keeping with the consolidated IFRS monetary statements

2) represents the common per 30 days money utilized in working and making an investment actions

The yearly file 2021 is to be had for obtain on our web site:

Subsequent Occasions

April 7, 2022 – Annual Normal Assembly Knowledge name

April 26, 2022 – Annual Normal Assembly

For additional data please touch:

For Buyers:

Hernan Levett

Leader Monetary Officer

Spexis AG.

+41 61 567 16 00

[email protected]

For Media:

Dr. Stephan Feldhaus

Feldhaus & Spouse

+41 79 865 92 56

[email protected]

About Spexis

Spexis is a clinical-stage biopharmaceutical corporate based totally in Allschwil, Switzerland, fascinated about uncommon sicknesses and oncology. The present pipeline of the corporate is a mix of 2 legacy corporations, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The blended corporate has been renamed to Spexis AG and is buying and selling at the SIX Swiss Change beneath the emblem SIX:SPEX. For additional data please talk over with: .


This press free up incorporates forward-looking statements that are in keeping with present assumptions and forecasts of Spexis control. Identified and unknown dangers, uncertainties, and different components may just result in subject material variations between the forward-looking statements made right here and the real building, particularly Spexis’ effects, monetary scenario, and function. Readers are cautioned to not put undue reliance on forward-looking statements, which talk simplest of the date of this conversation. Spexis disclaims any aim or legal responsibility to replace and revise any forward-looking statements, whether or not on account of new data, long run occasions or in a different way.

SOURCE: Polyphor AG

View supply model on